Apparently the cancer vaccine honeymoon is over. Despite what looked like promising early-stage clinical data, Pfizer (NYSE:PFE) has decided to end its collaboration with Celldex Therapeutics (Nasdaq:CLDX) for the anti-cancer immunotherapeutic CDX-110.

IN PICTURES: 8 Signs Of A Doomed Stock

While it is not unusual for small oncology-focused biotechs to trade down after the annual ASCO meeting - the most important oncology-related medical conference on the calendar - Celldex has done a bit worse than most. There had been fears that Pfizer's commitment was something less than complete, but Friday's announcement walloped Celldex's stock.

Where Does Celldex Go From Here?
Celldex is putting on a brave face for its shareholders. The company is vowing to continue developing the product on its own, presumably with an eye toward striking another deal with a larger pharmaceutical company somewhere down the road. Sometimes this works out - there are examples where a partner has dropped out and the drug still ultimately makes it to market. Unfortunately, companies like GenVec (Nasdaq:GNVC), Trubion (Nasdaq:TRBN) and Neurocrine Biosciences (Nasdaq:NBIX) have all found that the loss of Pfizer as a partner is not a good sign for the drug involved.

One is the Loneliest Number
While Celldex says that they do not need a partner, I believe they are mistaken. Celldex has about $66 million in cash and marketable securities on the balance sheet and Phase 3 clinical studies (to say nothing of preparations for a full-scale commercial launch) cost a lot of money. Brain cancer studies are not usually anything close to as large as a study for a diabetes drug, for example, so Celldex might be able to fund a study itself. That said, it would be a very tight squeeze, and any attempt to raise money with the stock in the doldrums is going to dilute existing shareholders pretty meaningfully.

Furthermore, the company has to weigh the benefits of going at it alone with the risks. The company has other drug candidates in various stages of development and funding multiple studies may deplete resources to a point where other programs have to be postponed. All in all, it would not be surprising if the company is talking tough more with the intention of signaling that they will not take a cut-rate desperation deal with another partner as opposed to a true intention to go it alone from here on out.

The Drug Seems Worth The Effort
Although skeptics can point to the fact that the drug targets only a sub-set of the glioblastoma patient population and that studies to date on CDX-110 have been small and lacked a control arm, the data has been encouraging. In fact, earlier studies have shown that 70-80% of patients getting the treatment can expect it to hold the disease in check for more than 8 months, and that is a significant advantage over historical controls. Moreover, though there have been some hypersensitivity reactions to the drug, the overall safety profile seems encouraging. In other words, this does look like a drug that is worth taking into Phase 3 studies.

Here again, it is a question of the risk-return tradeoffs. Does Celldex really want to put all of their eggs in the CDX-110 basket? It is not all that unusual for drugs to show promise in small Phase 2 studies only to fail in larger pivotal trials. Should the company risk the development of CDX-011 in breast cancer and melanoma to push ahead by itself?

The Bottom Line
There is no question that many investors will take Pfizer's decision as proof (or at least a strong indication) that CDX-110 is not good enough to get FDA approval for glioblastoma with EGFRvIII expression. That does not make it true - Pfizer may simply have decided that the market is too small, the pathway too uncertain, or the competition too formidable - but it makes it a real factor for the stock.

Quite frankly, shareholders who have held on this far and can handle the ongoing risks might want to sit tight. Biotechs are risky in the best of times and while Pfizer's decision certainly has to change the risk calculation, it does not carry the same weight as bad clinical data. Biotech stocks like Celldex should only be held in risk-tolerant and well-diversified portfolios to begin with, so for those investors who are not putting all their eggs in the Celldex basket, there may be just enough reason to keep hoping this stock could recover. (Learn how to find a healthy pharmaceutical investment in a market full of weak drugs. Check out Measuring The Medicine Makers.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  2. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  3. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  4. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  5. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  6. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  7. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  8. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  9. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  10. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
Trading Center